Paul Tudor Jones's PLRX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 29,729 shares of Pliant Therapeutics, Inc. (PLRX) worth $33,891, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in PLRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 29,932 shares. Largest reduction occurred in Q3 2023, reducing 27,725 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Pliant Therapeutics (PLRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pliant Therapeutics (PLRX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2025 | -203 | Reduce 0.68% | 29,729 | $1.16 |
| Q1 2025 | +29,932 | New Buy | 29,932 | $1.35 |
| Q4 2024 | -22,628 | Sold Out | 0 | $0.00 |
| Q3 2024 | -9,618 | Reduce 29.83% | 22,628 | $11.21 |
| Q2 2024 | +5,349 | Add 19.89% | 32,246 | $10.75 |
| Q1 2024 | +26,897 | New Buy | 26,897 | $14.90 |
| Q3 2023 | -27,725 | Sold Out | 0 | $0.00 |
| Q2 2023 | -18,482 | Reduce 40.00% | 27,725 | $18.12 |
| Q1 2023 | +22,078 | Add 91.50% | 46,207 | $0.03 |
| Q4 2022 | +153 | Add 0.64% | 24,129 | $0.02 |
| Q3 2022 | +23,976 | New Buy | 23,976 | $20.90 |
Paul Tudor Jones's Pliant Therapeutics Investment FAQs
Paul Tudor Jones first purchased Pliant Therapeutics, Inc. (PLRX) in Q3 2022, acquiring 23,976 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Pliant Therapeutics, Inc. (PLRX) for 15 quarters since Q3 2022.
Paul Tudor Jones's largest addition to Pliant Therapeutics, Inc. (PLRX) was in Q1 2025, adding 29,932 shares worth $40,408.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 29,729 shares of Pliant Therapeutics, Inc. (PLRX), valued at approximately $33,891.
As of the Q2 2026 filing, Pliant Therapeutics, Inc. (PLRX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Pliant Therapeutics, Inc. (PLRX) was 46,207 shares, as reported at the end of Q1 2023.